# Cyclacel Pharmaceuticals Inc. (CYCC)

Source: https://www.quantisnow.com/company/CYCC
Generated: 2026-11-16T00:36:26.879Z

- Ticker: CYCC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: cyclacel.com

## About

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

## Latest CYCC news and filings

- 2025-09-16 20:05 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6202419)
- 2025-09-16 19:31 UTC [SEC Form 3] [New insider Fitters Diversified Berhad claimed ownership of 699,158 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-fitters-diversified-berhad-claimed-ownership-of-699158-shares-6202323)
- 2025-09-12 10:09 UTC [SEC Form 425] [SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-cyclacel-pharmaceuticals-inc-6198720)
- 2025-09-12 10:07 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-completion-of-acquisition-6198719)
- 2025-09-12 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cyclacel-pharmaceuticals-inc-6198703)
- 2025-09-12 10:00 UTC [Public Offering] [Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.](https://www.quantisnow.com/insight/bio-green-med-solution-inc-announces-closing-of-strategic-acquisition-6198692)
- 2025-09-10 19:09 UTC [SEC Form 4] [Large owner Kua Khai Loon sold $133,569 worth of shares (19,054 units at $7.01), decreasing direct ownership by 5% to 385,411 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-kua-khai-loon-sold-133569-worth-of-shares-6196378)
- 2025-09-05 15:57 UTC [SEC Form 425] [SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-cyclacel-pharmaceuticals-inc-6191369)
- 2025-09-05 15:53 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-financial-statements-and-6191361)
- 2025-09-04 20:00 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6189925)
- 2025-09-04 20:00 UTC [SEC Form 4] [Large owner Ong Yee Lung acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-ong-yee-lung-acquired-186465-shares-increasing-direct-6189912)
- 2025-09-04 20:00 UTC [SEC Form 4] [Large owner Yap Kim Choy acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-yap-kim-choy-acquired-186465-shares-increasing-direct-6189910)
- 2025-09-04 20:00 UTC [SEC Form 4] [Large owner Kua Khai Loon acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-kua-khai-loon-acquired-186465-shares-increasing-direct-6189909)
- 2025-09-02 13:00 UTC [SEC Form POS AM filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cyclacel-pharmaceuticals-inc-6185263)
- 2025-09-02 10:06 UTC [SEC Form 3] [New insider Ong Yee Lung claimed ownership of 218,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-ong-yee-lung-claimed-ownership-of-218000-shares-6184560)
- 2025-09-02 10:06 UTC [SEC Form 3] [New insider Kua Khai Loon claimed ownership of 218,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-kua-khai-loon-claimed-ownership-of-218000-shares-6184559)
- 2025-09-02 10:06 UTC [SEC Form 3] [New insider Yap Kim Choy claimed ownership of 218,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-yap-kim-choy-claimed-ownership-of-218000-shares-6184557)
- 2025-09-02 10:02 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6184526)
- 2025-08-28 10:10 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-changes-in-registrants-6181545)
- 2025-08-25 18:51 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-cyclacel-pharmaceuticals-inc-6177485)
- 2025-08-25 18:48 UTC [SEC Form 425] [SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-cyclacel-pharmaceuticals-inc-6177482)
- 2025-08-25 18:47 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-cyclacel-pharmaceuticals-inc-6177480)
- 2025-08-21 22:50 UTC [SEC Form POS AM filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cyclacel-pharmaceuticals-inc-6175523)
- 2025-08-14 01:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-cyclacel-pharmaceuticals-inc-6164150)
- 2025-08-13 21:27 UTC [SEC Form 425] [SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-cyclacel-pharmaceuticals-inc-6163811)
- 2025-08-13 21:27 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6163809)
- 2025-08-13 20:05 UTC [Dividends] [Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-reports-second-quarter-financial-results-and-provides-business-6162932)
- 2025-08-13 10:17 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-financial-statements-and-6161864)
- 2025-08-08 14:52 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-cyclacel-pharmaceuticals-inc-6155804)
- 2025-08-05 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cyclacel-pharmaceuticals-inc-6145901)
- 2025-08-04 23:23 UTC [SEC Form 4] [Large owner Lazar David E. sold $83,430 worth of shares (6,750 units at $12.36), decreasing direct ownership by 4% to 155,838 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-lazar-david-e-sold-83430-worth-of-shares-6145698)
- 2025-08-04 22:50 UTC [CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-highlights-preclinical-data-showing-that-cancer-of-the-6145665)
- 2025-07-31 00:31 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-cyclacel-pharmaceuticals-inc-6139528)
- 2025-07-28 20:06 UTC [SEC Form 8-K] [Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cyclacel-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-6134339)
- 2025-07-25 21:13 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-cyclacel-pharmaceuticals-inc-6133364)
- 2025-07-24 01:58 UTC [SEC Form S-4] [SEC Form S-4 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-4-filed-by-cyclacel-pharmaceuticals-inc-6130504)
- 2025-07-24 01:58 UTC [SEC Form S-1] [SEC Form S-1 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-cyclacel-pharmaceuticals-inc-6130490)
- 2025-07-24 01:58 UTC [SEC Form POS AM filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cyclacel-pharmaceuticals-inc-6130489)
- 2025-07-24 01:58 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-cyclacel-pharmaceuticals-inc-6130488)
- 2025-07-16 13:01 UTC [SEC Form 425] [SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-cyclacel-pharmaceuticals-inc-6121643)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CYCC
- Earnings history: https://www.quantisnow.com/earnings/CYCC
- Dividend history: https://www.quantisnow.com/dividends/CYCC
- Insider transactions: https://www.quantisnow.com/insiders/CYCC
- Options chain: https://www.quantisnow.com/options/CYCC
- SEC 8-K filings only: https://www.quantisnow.com/company/CYCC/8-k
- RSS and alerts for CYCC: https://www.quantisnow.com/docs/rss-feeds.md
